Weight Gain May Increase Risk of Breast Cancer in Postmenopausal Women

Publication
Article
OncologyONCOLOGY Vol 20 No 9
Volume 20
Issue 9

Weight gain, particularly after menopause, is associated with an increased risk of breast cancer in women

Weight gain, particularly after menopause, is associated with an increased risk of breast cancer in women, according to an article in a recent issue of JAMA (296:193-201, 2006).

Background information in the article indicates that weight loss after menopause lowers circulating estrogen hormones in women, and because estrogen is directly related to breast cancer, weight loss is thought to decrease risk of the disease. Studies show that weight gain since early adulthood is associated with increased breast cancer risk in postmenopausal women, particularly those not taking postmenopausal hormones. However, weight changes in middle-aged to older women (50 years and older) has been studied less extensively.

Two Age Periods Studied

A. Heather Eliassen, SCD, of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues analyzed data within the Nurses' Health Study to determine the association between weight change and the risk of breast cancer among postmenopausal women. The researchers assessed weight change for two different periods—since 18 years of age and since menopause. A total of 87,143 postmenopausal women (ages 30 to 55 years) were followed up for up to 26 years to analyze weight change since age 18. Weight change since menopause was assessed among 49,514 women (followed up for up to 24 years).

Women who gained about 55 lb or more since age 18 were at a 45% increased risk of breast cancer, compared with those who maintained their weight, with a stronger association among women who have never taken postmenopausal hormones. Women who gained about 22 lb or more since menopause were at an 18% increased risk of breast cancer. Those who lost about 22 lb or more since menopause (and kept the weight off) and had never used postmenopausal hormones were at a 57% lower risk of breast cancer than those who simply maintained their weight. The researchers concluded that 15% of the study's breast cancer cases may be attributable to weight gain of 4.4 lb or more since age 18, and 4.4% of the cases may be attributable to weight gain of 4.4 lb or more since menopause.

"These data suggest that weight gain during adult life, specifically since menopause, increases the risk of breast cancer among postmenopausal women, whereas weight loss after menopause is associated with a decreased risk of breast cancer," the authors write. "Women should be advised to avoid weight gain both before and after menopause to decrease their postmenopausal breast cancer risk.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.